Children with Autism Spectrum Disorder (ASD) see a “significant” improvement in symptoms and less reliance on other medications after treatment with Tikun Olam’s Avidekel™ medical cannabis, as confirmed by a new study, conducted in Israel, and published in the Scientific Journal Review.
The two-year study, “Real Life Experience Of Medical Cannabis Treatment In Autism: Analysis Of Safety And Efficacy,” followed 188 children (average age: 13) diagnosed with ASD. The patients were treated with Tikun Olam’s high-CBD, low-THC medical cannabis strains, which have been specifically cultivated and shown to provide symptom relief for ASD and related conditions with minimal psychoactive effect.
At the study’s outset, the most common patient symptoms were restlessness (90.4%), rage attacks (79.8%), and agitation (78.7%). After six months of daily cannabis treatment at Tikun Olam clinics in Israel, 80.1% of patients reported improvement of their symptoms, with 30.1% reporting “significant” improvement. Other key findings include:
- Of 27 patients who had epilepsy, 24 reported improved or disappearance of symptoms;
- 34% of patients decreased other medications; and
- 20% of patients stopped using antipsychotic medication.
“Autism is a leading condition of concern worldwide, so this study couldn’t have come at a better time,” says Dr. Annabelle Manalo, PhD, Tikun Olam’s Science Director. “The data shows that autism patients can improve their overall quality of life utilizing a high CBD strain, and most importantly, that young users can safely and effectively benefit from medical cannabis.”
“With this study, cannabis is shown to be an effective choice for parents looking for the safest and most neuroprotective treatment.”
Side effects to cannabis treatment were minimal, with the most common at six months reported as restlessness (6.6%), sleepiness (3.2%), psychoactive effect (3.2%).
Tikun Olam (“repair the world” in Hebrew) is the world’s leading cannabis brand and globally recognized as the pioneer of modern medical cannabis. Its products have been used since 2010 to treat over 20,000 patients for symptoms of medical conditions including cancer, PTSD, AIDS, epilepsy, Crohn’s Disease/colitis, multiple sclerosis, cerebral palsy, chronic pain, and neuropathy.
Tikun Olam’s proprietary cannabis were developed over years of clinical research and include the first-ever, high-CBD, “high-less” strain, Avidekel™. Tikun Olam operates partnerships in Israel, the US, Canada, and Australia in support of its global mission to educate the world about cannabis as a scientifically proven wellness product. The company is online at www.tikunolamusa.com.
Source: Tikun Olam
